SCHEMBL2232860

SCHEMBL2232860

COC(=O)NN(C(=O)Oc1ccccc1OC)c1ccccc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.44
STAT3 P40763 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
LIPE Q05469 1/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
PRSS1 P07477 1/20 0.38
ACR P10323 1/20 0.38
BCHE P06276 1/20 0.38
CTSD P07339 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235392 0.90 POLB (0.41) ATMSTAT3L3MBTL1LIPEPOLB
SCHEMBL2235417 0.89 KMT2A (0.43) STAT3L3MBTL1SMN1; SMN2ALDH1A1MAPT
SCHEMBL2232497 0.86 MAPT (0.41) ATMSTAT3LIPEPOLBSMN1; SMN2
SCHEMBL2236294 0.85 ATM (0.47) ATML3MBTL1LIPEPOLBSMN1; SMN2
SCHEMBL11620797 0.83 STAT3 (0.43) ATMSTAT3L3MBTL1CA12CA1
SCHEMBL2233414 0.82 LIPE (0.53) LIPEMAPTKMT2A
SCHEMBL2233290 0.81 ALDH1A1 (0.50) ATMSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL27606694 0.80 ALDH1A1 (0.44) CA12CA1CA2CA4CA7
SCHEMBL2237995 0.79 HPGD (0.41) POLBSMN1; SMN2HSD17B10ALDH1A1MAPT
SCHEMBL2236089 0.77 ALDH1A1 (0.43) POLBHSD17B10ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR ATM 540/4885STAT3 3718/4885L3MBTL1 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.